

Journal section: Oral Surgery  
 Publication Types: Research

doi:10.4317/medoral.24274

## Effect of antibiotic prophylaxis for preventing infectious complications following impacted mandibular third molar surgery. A randomized controlled trial

Nicolás Yanine <sup>1,2,3</sup>, Nicole Sabelle <sup>1</sup>, Valentina Vergara-Gárate <sup>1</sup>, Josefina Salazar <sup>1</sup>, Ignacio Araya-Cabello <sup>1</sup>, Alonso Carrasco-Labra <sup>4,5</sup>, Conchita Martín <sup>6</sup>, Julio Villanueva <sup>1,2</sup>

<sup>1</sup> Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, University of Chile, Santiago, Chile

<sup>2</sup> Maxillofacial Surgery Unit, San Borja Arriarán Clinical Hospital, Chile

<sup>3</sup> Maxillofacial Surgery Unit, Alemana Clinic of Santiago, Chile

<sup>4</sup> Department of Evidence Synthesis and Translation Research, Science and Research Institute, American Dental Association, Chicago, IL, USA

<sup>5</sup> Department of Oral and Craniofacial Health Science, School of Dentistry, University of North Carolina at Chapel Hill, NC, USA

<sup>6</sup> BIOCRAN (Craniofacial Biology) Research Group, University Complutense, Madrid, Spain

### Correspondence:

Department of Oral and Maxillofacial Surgery  
 Faculty of Dentistry, University of Chile  
 Olivos 943, Independencia, Santiago, ZC 8380544, Chile  
 nyanine@uchile.cl

Received: 25/08/2020

Accepted: 23/08/2021

Yanine N, Sabelle N, Vergara-Gárate V, Salazar J, Araya-Cabello I, Carrasco-Labra A, *et al.* Effect of antibiotic prophylaxis for preventing infectious complications following impacted mandibular third molar surgery. A randomized controlled trial. Med Oral Patol Oral Cir Bucal. 2021 Nov 1;26 (6):e703-10.

Article Number: 24274 <http://www.medicinaoral.com/>  
 © Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946  
 eMail: [medicina@medicinaoral.com](mailto:medicina@medicinaoral.com)  
**Indexed in:**  
 Science Citation Index Expanded  
 Journal Citation Reports  
 Index Medicus, MEDLINE, PubMed  
 Scopus, Embase and Emcare  
 Índice Médico Español

### Abstract

**Background:** The objective of this study was to determine the effect of antibiotic prophylaxis in preventing postoperative infections after extraction of impacted mandibular third molars.

**Material and Methods:** A Parallel-group, randomized, blind, placebo-controlled trial was performed. 154 patients were randomly allocated to 2 groups; experimental (n=77) receiving 2g amoxicillin 1 hour prior to surgery and control (n=77) receiving placebo. Primary outcome was postoperative infections and secondary outcome was the need for rescue analgesia.

**Results:** 4.5% of patients developed postoperative infections, five patients of the control group (4 alveolar osteitis, 1 surgical site infection) and two of the experimental group (1 alveolar osteitis, 1 surgical site infection). Difference between groups was not statistically significant, RR=0.4 (95%CI 0.08-1.99,  $p=0.41$ ) NNTB=26. Rescue analgesia intake was significantly higher in the control group (41 vs 18 patients of experimental group) RR=0.49 (95%CI 0.32-0.75,  $p<0.05$ ) NNTB=3.

**Conclusions:** The use of 2g amoxicillin 1 hour before surgery was not effective in significantly reducing the risk of postoperative infections from impacted mandibular third molars extraction, when compared to placebo. Nevertheless, antibiotic prophylaxis was associated with a reduced need for rescue analgesia.

**Key words:** Antibiotic prophylaxis, third molar, tooth extraction, impacted tooth, dry socket, surgical wound infection, oral surgery.

## Introduction

The surgical extraction of mandibular third molars is the most common procedure in oral and maxillofacial surgery worldwide. These type of tooth are completely or partially unerupted and positioned against another tooth, bone or soft tissue in a way that its further eruption is unlikely (1). This alteration in the eruption is mainly due to the fact that third molars are the last group of teeth to complete their formation, root development and eruption, and they do so on a defined continent, the dentoalveolar skeletal structure of the maxilla. Postoperative complications of this procedure include pain, edema, trismus, fever, dry socket, and purulent drainage. These complications have an impact on patients' lives, potentially affecting the normal development of daily activities, such as eating, speaking, and maintaining oral hygiene (2). Surgical site infection is one of the most frequent postoperative complications after the extraction of an impacted mandibular third molars (IMTM) (3). The frequency of these postoperative complications varies in the literature between 0% and 16% (4-10).

The surgical site infection is triggered when there is a quantitatively and qualitatively significant bacterial threat. The risk of infection varies according to the type of procedure, the presence of active local infection, the surgical time, and the patient's underlying conditions, such as obesity, decompensated diabetes, or immunosuppression. The frequency of these postoperative complications varies in the literature between 0% and 16% (4-10). The prevention of surgical site infection should focus on reducing the number of bacteria in the surgical wound and improving the patient's immune response.

A widespread practice among dentists is the use of antibiotic prophylaxis (AP), which consists in the administration of antibiotics before surgery to significantly reduce infection and minimizing adverse effects (2). However, its indication is still widely debated (11). A recent evidence summary on the use of antibiotics in oral and maxillofacial surgery found conflicting results from both clinical trials and systematic reviews, regarding their effectiveness as prophylaxis for third molar extraction (12). Furthermore, systematic reviews have failed to reach consensus due to several factors, one of which is the serious methodological flaws of the included trials (13,14).

The objective of this study was to determine the effect of antibiotic prophylaxis, compared to placebo, in reducing the risk of postoperative infections in patients undergoing impacted mandibular third molar extraction. A secondary objective was to compare the need of rescue analgesia between both groups.

## Material and Methods

### - Trial design

The study design was a randomized, parallel-group, blinded and placebo-controlled clinical trial, with a 1:1

assignment of participants to arms. This trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12617001498381 and follows the recommendations from the Consolidated Standards of Reporting Trials (CONSORT) statement (15).

### - Participants

Patients with ages ranging between 15 to 35 years, with no comorbidities, that presented at the Maxillofacial Surgery Department of San Borja Arriarán Hospital in Santiago de Chile between the years 2017 and 2019, with at least one clinically and radiographically IMTM with its crown partially covered by mucosa, in position B, class II according to the Pell and Gregory classification (16), were included. Pregnant women, immunocompromised subjects, patients with allergy to penicillin and its derivatives or to nonsteroidal anti-inflammatory drugs (medically diagnosed or patient-reported allergy), patients with gastric ulcer, or that were on antibiotics in the last 30 days before surgery, or those who had an episode of pericoronitis up to 7 days before the intervention were excluded. This study was approved by the institutional ethical review board of the corresponding service. Written informed consent was obtained from all patients.

### - Interventions

Patients were allocated either to an experimental group to receive 2g amoxicillin (four 500mg capsules, Andrómaco/Grünenthal. Santiago, Chile) one hour before the third molar extraction or to a control group, which received placebo (four capsules, Cruz Verde Pharmacy Laboratory. Santiago, Chile) one hour before surgery. All procedures were conducted by 3 maxillofacial surgeons with at least 2 years of experience in an ambulatory oral surgery operating room. All patients had only one third molar removed per session. The surgical protocol was as follows: local anesthesia was performed using the Spix technique and superficial cervical plexus block with two cartridges of 1.8 ml of 2% lidocaine with epinephrine (1:100,000) each, per surgical site. A full thickness triangular mucoperiosteal flap (semi Neumann) was created, osteotomy and/or tooth sectioning were performed as conservative as possible, using a low speed round bur and abundant irrigation with 0.9% saline. Osteotomy was classified as mild ( $\frac{1}{3}$  of dental crown height), moderate ( $\frac{2}{3}$  of dental crown height or first third of the root) or major (over  $\frac{2}{3}$  of dental crown height or second third of the root). Straight elevators were used for every extraction. After the complete extraction of the molar, the excision of pericoronal hyperplastic tissue and alveolar socket conditioning were performed. Immediately after, the socket was profusely irrigated with saline 0.9% for 30 seconds. Silk 3.0 suture was used for the surgical wound closing, without the additional use of any intra or extra alveolar dressing or antiseptic. Finally, postoperative written instructions were explained to all

patients (Appendix 3). All patients received a prescription for 400mg ibuprofen tablets and 500mg paracetamol tablets every 8 hours for 3 days as anti-inflammatory medication and postoperative analgesic. When patients needed additional pain management or they reported experiencing pain greater than 4 when using a 0 to 10 visual analogue scale, 125 mg lysine clonixinate tablets were prescribed as rescue analgesia, repeating the dose according to the requirements of each patient.

#### - Outcomes

The primary outcome was the presence of postoperative infectious complications, described as alveolar osteitis or surgical site infection. Alveolar osteitis was defined as postoperative pain inside and around the extraction site that increased in severity between the first and third day after extraction, along with a partially or completely disintegrated blood clot in the alveolar socket, with or without halitosis (17). Assessment was performed by in-person clinical examination. This process was performed by 2 calibrated researchers (kappa 0,95) who participated exclusively in this phase of the study. Postoperative controls were performed at 3-, 7- and 30-days post-surgery. Surgical site infection was adjudicated when the patient presented at least one of the following: A: Purulent drainage from the surgical wound or abscess. B: Isolation of pathogenic microorganisms in liquid or tissue cultures from the surgical site. C: Spontaneous dehiscence of the incision site in patients who exhibit at least one of the following signs or symptoms: 1) fever ( $>38^{\circ}\text{C}$ ), 2) pain from palpation or spontaneous, 3) localized swelling, facial erythema or local heat. D: Severe pain after a week, together with moderate or severe intraoral inflammation and/or moderate or severe intraoral erythema with no other apparent cause, that improves with antibiotic treatment (18).

The secondary outcome was the need of rescue analgesia. Rescue analgesia was defined as the need for an additional dose of analgesic was necessary for the management of persistent pain, and this did not replace or delay the next dose of the first prescribed analgesic. The rescue medication used was lysine clonixinate in 125 mg tablets. We also evaluated adverse reactions related to the use of amoxicillin, defined as follows: 1) Allergic reaction: urticaria and/or angioedema, 2) Anaphylaxis: throat or tongue swelling and/or respiratory symptoms. 3) Gastrointestinal reactions: nausea, vomiting, abdominal pain and diarrhea. Assessment was performed by anamnesis during clinical examinations.

#### - Sample size

A priori sample size was calculated assuming a 15% infection rate in the control group and 2% in the experimental group (type I error: 0.05 and 80% power), and a potential 10% of withdrawal or lost to follow-up. Based on this we estimated that we would need to recruit 154 patients in total.

#### - Randomization and allocation concealment

Randomization was performed in permuted blocks through a computer-generated list of random numbers (Stata V11.0). The placebo capsules were the same size, color and texture as the amoxicillin capsules and allocation concealment was performed using sequentially numbered and identical containers, which were labelled and prepared in an external facility that kept the randomization sequence concealed from the investigators and clinicians while enrolling participants. Each container was labelled with an additional code to identify the chosen side for the surgery (left or right third molar). In patients presenting with more than one IMTM, the tooth to be extracted between either side was also randomly selected.

#### - Blinding

Both the surgeon and the patients remained blind for the duration of the study. Outcome assessor, data collector, statistician, health care institution and clinical trial monitor were also blind to the participants' study arm.

#### - Statistical methods

The difference in proportions between groups was calculated using the chi-square test with a significance level of 5% (SPSS Statistics V22.0). To determine the magnitude of the effect of the intervention in the outcomes of interest, absolute (number needed to treat for benefit NNTB) and relative measures (relative risk) were calculated along with their 95% confidence interval.

In the event of detecting crossing over of participants from one arm of the study to the other, Intention-to-treat analysis was planned. In the case of withdrawals or lost to follow-up during the course of the trial, methods using a plausible range from more (e.g., worst case scenario) to less stringent results were applied to evaluate the robustness of the findings to missing participant data. A test for interaction (subgroup analysis) was planned performing a multivariate analysis to determine the extent to which smoking (cigarettes or cannabis sativa), alcohol consumption, operative time, osteotomy, the need for tooth sectioning (need of tooth sectioning vs no need for tooth sectioning) may associated with infectious complications. These analyses used baseline exposure assessments, intraoperative findings and were restricted to participants with nonmissing subgroup data at baseline.

## Results

A total of 154 patients entered this clinical trial and were randomly allocated to two groups. No substantial differences were identified among participants baseline characteristics between arms. (Table 1).


Three patients declined to complete follow up due to personal reasons (2 from the control group and 1 from the experimental group). Two patients were excluded because of self-medication with antibiotics during the follow up period without signs of infection. (CONSORT Flow Diagram, Fig. 1 and Fig. 2).

**Table 1:** Clinical and demographic characteristics.

|                       | EXPERIMENTAL GROUP<br>(Antibiotic prophylaxis) | CONTROL GROUP<br>(Placebo) | TOTAL  | Mean (SD)         |
|-----------------------|--|----------------------------|--------|-------------------|
| n                     | 74-3#  | 75-2#                      | 149-5# | -                 |
| Age                   | 21,1 (4,3)                                     | 21,9 (4,7)                 | -      | 21,5 (4,5)        |
| Female sex (F)        | 55   | 52                         | 107    | -                 |
| Male sex (M)          | 22   | 25                         | 47     | -                 |
| Left third molar (L)  | 48   | 37                         | 85     | -                 |
| Right third molar (R) | 29   | 40                         | 69     | -                 |
| Operative time*       | 11min 17s (6min 10s)                           | 11min 55s (7min 49s)       | -      | 11min 36s (6 min) |
| Osteotomy             | 51   | 48                         | 99     | -                 |
| Tooth sectioning      | 46   | 44                         | 90     | -                 |
| Smokers               | 22   | 21                         | 43     | -                 |
| Alcohol               | 22   | 22                         | 44     | -                 |
| Marihuana             | 7  | 4                          | 11     | -                 |

\* Operative time measured in minutes and seconds, starting when the first incision was made.

# Three patients from the experimental group and two patients from the placebo group were excluded. Data analyzes were performed including and excluding these individuals, without observing differences in the results.



**Fig. 1:** CONSORT Flow Diagram.

**CONSORT 2010 checklist of information to include when reporting a randomised trial\***

| Section/Topic                           | Item No                  | Checklist Item  | Reported on page No | Statistical methods |
|---|--------------------------|---|---------------------|---------------------|
| <b>Title and abstract</b>               | 1a                       | Identification as a randomised trial in the title   | e1                  |                     |
|   | 1b                       | Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)   | e1                  |                     |
| <b>Introduction</b>                     | 2a                       | Scientific background and explanation of rationale  | e2                  |                     |
|   | 2b                       | Specific objectives or hypotheses   | e2                  |                     |
| <b>Methods</b>                          | 3a                       | Description of trial design (such as parallel, factorial) including allocation ratio  | e2                  |                     |
|   | 3b                       | Important changes to methods after trial commencement (such as eligibility criteria), with reasons  | Not applicable      |                     |
| <b>Participants</b>                     | 4a                       | Eligibility criteria for participants   | e2                  |                     |
|   | 4b                       | Settings and locations where the data were collected  | e2                  |                     |
| <b>Interventions</b>                    | 5                        | The interventions for each group with sufficient details to allow replication, including how and when they were actually administered   | e2, e3              |                     |
| <b>Outcomes</b>                         | 6a                       | Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed  | e3                  |                     |
|   | 6b                       | Any changes to trial outcomes after the trial commenced, with reasons   | Not applicable      |                     |
| <b>Sample size</b>                      | 7a                       | How sample size was determined  | e3                  |                     |
|   | 7b                       | When applicable, explanation of any interim analyses and stopping guidelines  | Not applicable      |                     |
| <b>Randomisation</b>                    | 8a                       | Method used to generate the random allocation sequence  | e3                  |                     |
|   | 8b                       | Type of randomisation; details of any restriction (such as blocking and block size)   | e3                  |                     |
| <b>Allocation concealment mechanism</b> | 9                        | Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned | e3                  |                     |
| <b>Implementation</b>                   | 10                       | Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions   | e3                  |                     |
| <b>Blinding</b>                         | 11a                      | If done, who was blinded after assignment to interventions (for example, participants, care providers, those  | e3                  |                     |
|   |                          | assessing outcomes) and how   |                     |                     |
|   | 11b                      | If relevant, description of the similarity of interventions   |                     | e3                  |
|   | 12a                      | Statistical methods used to compare groups for primary and secondary outcomes   |                     | e3                  |
|   | 12b                      | Methods for additional analyses, such as subgroup analyses and adjusted analyses  |                     | e4                  |
|   | 13a                      | For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome  |                     | e4                  |
|   | 13b                      | For each group, losses and exclusions after randomisation, together with reasons  |                     | e4, e5              |
|   | 14a                      | Dates defining the periods of recruitment and follow-up   |                     | e2                  |
|   | 14b                      | Why the trial ended or was stopped  |                     | Not applicable      |
|   | 15                       | A table showing baseline demographic and clinical characteristics for each group  |                     | e4                  |
|   | 16                       | For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups   |                     | e4, e5, e6          |
|   | 17a                      | For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)   |                     | e4                  |
|   | 17b                      | For binary outcomes, presentation of both absolute and relative effect sizes is recommended   |                     | e4                  |
|   | 18                       | Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory   |                     | e4                  |
|   | 19                       | All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)   |                     | e4                  |
|   | <b>Discussion</b>        |   |                     |                     |
|   | 20                       | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses  |                     | e8                  |
|   | 21                       | Generalisability (external validity, applicability) of the trial findings   |                     | e7, e8              |
|   | 22                       | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence   |                     | e7, e8              |
|   | <b>Other information</b> |   |                     |                     |
|   | 23                       | Registration number and name of trial registry  |                     | e2                  |
|   | 24                       | Where the full trial protocol can be accessed, if available   |                     | e2                  |
|   | 25                       | Sources of funding and other support (such as supply of drugs), role of funders   |                     | e9                  |

\*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for 99.16.166 references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).

Fig. 2: CONSORT checklist of information to include when reporting a randomised trial.

None of these patients had postoperative infectious complications at the time of exclusion and when performing best-case and worst-case scenario analysis, results did not vary.

Postoperative infections occurred in 4.5% of all patients studied (n= 154 patients). Table 2 summarizes the characteristics of these patients. Five of them were in the control group: 4 presented alveolar osteitis and 1 presented surgical site infection that manifested as submucosal abscess. In the experimental group, 2 patients presented postoperative infectious complications: one alveolar osteitis and one surgical site infection, also

manifested as submucosal abscess (Table 3). The risk reduction of infectious complications was not significantly different between antibiotic prophylaxis group and placebo group. (RR=0.4 95%CI 0.08-1.99, p=0.41). For the secondary outcome, 41 patients of the control group required rescue analgesia (all within the first week after surgery), while in the experimental group only 18 patients needed it (Table 4). Patients receiving antibiotics prophylactically (2 grs of amoxicillin) experienced a 51% reduction in the need of rescue analgesia compared to those in the control arm. RR=0.49 (95%CI 0.32-0.75, p=0.03) and NNTB=3.

Table 2: Characteristics of the patients who presented infections.

|  | No infectious complication | Alveolar osteitis       | Surgical site infection | Total | Mean (SD)              |
|--|----------------------------|-------------------------|-------------------------|-------|------------------------|
| N  | 142-#5                     | 5                       | 2                       | 154   | -                      |
| Age  | 20,93(4.2)                 | 28.5(6.5)               | 16.5 (1.5)              | -     | 21,5 (4,5)             |
| Female sex (F)   | 100-#3                     | 3                       | 1                       | 107   | -                      |
| Male sex (M)   | 42#2                       | 2                       | 1                       | 47    | -                      |
| Left third molar (L)   | 82                         | 2                       | 1                       | 85    | -                      |
| Right third molar (R)  | 66                         | 2                       | 1                       | 69    | -                      |
| Operative time*  | 12 min 4 s (7min 46 s)     | 15 min 14 s (6 min 15s) | 11 min 44s (6 min 43 s) | -     | 12 min 11s (7 min 43s) |
| Subperiosteal approach only (no osteotomy, no odontosection)** | 53                         | 0                       | 1                       | 54    | -                      |
| Subperiosteal approach and Osteotomy**                         | 94                         | 4                       | 1                       | 99    | -                      |
| Subperiosteal approach and Odontosection**                     | 86                         | 3                       | 1                       | 90    | -                      |
| Subperiosteal approach, Osteotomy and Odontosection**          | 51                         | 3                       | 1                       | 54    | -                      |
| Smokers  | 42                         | 1                       | 0                       | 43    | -                      |
| Alcohol  | 42                         | 1                       | 1                       | 44    | -                      |
| Drugs  | 10                         | 0                       | 1                       | 11    | -                      |

\* Operative time measured in minutes and seconds, starting when the first incision was made.

# Five patients who had no complications were excluded. Data analyzes were done including and excluding these individuals, without observing differences in the results.

\*\* Statistically significant difference was not detected comparing the risk of infectious complications among groups (Subperiosteal approach only, Osteotomy, Odontosection, Osteotomy and Odontosection).

**Table 3:** Infectious complications.

|                                   | No infectious complication | Alveolar osteitis | Surgical site infection | Total |
|-----------------------------------|----------------------------|-------------------|-------------------------|-------|
| Group A<br>Antibiotic prophylaxis | 72-3#                      | 1                 | 1                       | 77    |
| Group B<br>Placebo                | 70-2#                      | 4                 | 1                       | 77    |
| Total                             | 147                        | 5                 | 2                       | 154   |

**Table 4:** Rescue Analgesia.

|                                   | No Rescue Analgesia | Rescue Analgesia | Total |
|-----------------------------------|---------------------|------------------|-------|
| Group A<br>Antibiotic prophylaxis | 57-2#               | 18               | 77    |
| Group B<br>Placebo                | 34-2#               | 41               | 77    |
| Total                             | 95                  | 59               | 154   |

RR 0,49 (CI95% 0,32-0,75,  $p < 0.05$ . NNTB 3.

# Three patients from the experimental group and two patients from the placebo group were excluded. Data analyzes were performed including and excluding these individuals, without observing differences in the results.

Smoking (cigarettes or cannabis sativa) and alcohol consumption were not associated with an increased risk of infectious complications or with the use of rescue medication. Neither were operative times, degree of osteotomy or need of tooth sectioning. None of the patients reported adverse drug reactions during the study period.

**Discussion**

In the present trial, participants undergoing IMTM extraction and receiving AP seemed to not experience less postoperative complications compared to those in the control arm, however the requirement for rescue medication associated with postoperative pain in the AP group decreased.

On the incidence of postoperative infections, Lang *et al.* (19) reported 5.7% of infectious complications in a sample of 2,954 patients and Reiland *et al.* (20) reported a 8.5% in a sample of 1,895 patients that underwent third molar extraction at the Mayo Clinic in Rochester. These studies provide a good epidemiological approximation due to the large sample size, which is difficult to achieve in a clinical trial.

In the present study, of the total of patients included, 4.5% presented infectious complications. This percentage is similar to a recent trial that recruited 118 patients and reported a 5,9% of postoperative infections (21). However, among clinical trials there is great variability ranging from 0% to 16% (4-10).

The difference in postoperative complications between groups in this trial was not statistically significant, with 6.5% of the control group and 2.6% of the experimental group presenting infectious complications. A 2015 clinical trial showed similar results, with

an incidence of 8.6% in the control group and 3.3% in the experimental group, also without significant difference between groups, but unlike our study, this only included intraosseous third molars, which could decrease the risk of infection when compared to third molars that are communicated with the oral cavity (21). A 2017 study reported an incidence of infectious complications of 5% in the group receiving antibiotics and 7.5% in the control group (20). These figures are similar to the present study, however, there are several reports where the group that did not receive antibiotic prophylaxis reached an incidence of infections greater than 12% (2,9,22).

All the systematic reviews published up to date suggest that antibiotic prophylaxis may be effective for reducing postoperative complications when extracting mandibular third molars (3,13,23,24). However, most of the primary studies included in these reviews presented serious limitations of study design, which made them prone to risk of bias. More recent trials with better methodological quality and greater statistical power, have failed to find significant results to support the routine use of antibiotics to prevent infectious complications in healthy patients. (21,25). One possible reason to explain the heterogeneity of results in the literature could be the suboptimal reporting and variability in outcome definitions with regards to infectious complications. Another possible reason is the presence of confounding factors such as the use of intra and extra alveolar antiseptics as co-interventions (4,7). Lastly, many of the studies do not specify if there are differences between groups regarding the position of the third molar, which is a factor that could have an important role in the incidence of infec-

tious complications (4).

These reasons could explain this controversy, with some authors recommending its use to prevent infectious complications (2,4,5,7) and others reporting that not only is not effective, but it may be harmful, associating its use with an increase in hypersensitivity and adverse reactions, together with more costs for patients (6,9,26,27).

Regarding the use of rescue analgesia, 23% of the patients in the experimental group compared to 53% of the control group required it. This translates into a 51% decrease in the risk of need of rescue analgesia in the group that received AP (RR=0.49 95%CI 0.32-0.75,  $p<0.05$ ), or expressed in another way, for every 3 patients treated with AP, the benefit of avoiding the use of rescue analgesia in one additional patient is obtained. Other randomized clinical trials also reported a significant decrease in postoperative pain and a reduced need for rescue analgesia in patients who received AP (2,7,28). A non-randomized clinical trial conducted Grossi *et al.* in 2007 reported that patients who do not receive antibiotics are at twice the risk of complications associated with postoperative pain (29). On the other hand, a series of reports found no association between the use of AP and reduction in postoperative pain, edema or trismus (6,9,26,27).

The association between the use of antibiotics and the improvement of postoperative symptoms could be explained by the decrease in bacterial contamination of the surgical wound. This in turn would decrease inflammatory mediators, reducing postoperative pain without necessarily affecting the proportion of postoperative infections (30).

Lysine clonixinate was used as rescue analgesia since it can be taken as an additional dose for the management of persistent pain without modifying the analgesic scheme initially prescribed. This prostaglandin inhibitor is rapidly absorbed and takes about 60 minutes to achieve optimal plasma concentration. The drugs used in the primary analgesic and anti-inflammatory scheme in this clinical trial were paracetamol and ibuprofen, both widely used and with sufficient evidence to justify their use in the management of postoperative pain and edema after third molar extraction. The measurement of postoperative edema was not within the objectives of this clinical trial.

For the rest of the variables analysed such as osteotomies, tooth sectioning, operative times, side and position of the third molar, we did not find associations between them and the risk of postoperative infection (Table 2).

The results obtained from this trial showed that the use of 2g amoxicillin one hour before surgery was not effective in reducing the risk of postoperative infectious complications of IMTM extraction in healthy patients.

The patients who received antibiotics presented significantly less postoperative pain, however the administration of antibiotic prophylaxis is not justified for this purpose. Future research should be focused on if an adequate preoperative analgesic scheme may achieve similar results in postoperative pain experience.

In conclusion, the use of 2g amoxicillin 1 hour before surgery was not effective in significantly reducing the risk of postoperative infectious complications from IMTM extraction, when compared to placebo. The use of antibiotic prophylaxis was associated with a reduced need for rescue analgesia.

#### - Strengths and limitations

The present study was conducted following high standards of methodology to control possible sources of bias and the protocol was designed carefully to prevent methodology issues reported in other publications.

We obtained a smaller difference in infection rates between groups than what we assumed initially when sample size was calculated. This resulted in a wide confidence interval and could explain why antibiotic prophylaxis was not able to demonstrate significant differences.

#### References

1. Santosh P. Impacted Mandibular Third Molars: Review of Literature and a Proposal of a Combined Clinical and Radiological Classification. *Ann Med Health Sci Res.* 2015;5:229-34.
2. Lacasa JM, Jimenez JA, Ferras V, Bossom M, Sola-Morales O, Garcia-Rey C, *et al.* Prophylaxis versus pre-emptive treatment for infective and inflammatory complications of surgical third molar removal: a randomized, double-blind, placebo-controlled, clinical trial with sustained release amoxicillin/clavulanic acid (1000/62.5 mg). *Int J Oral Maxillofac Surg.* 2007;36:321-7.
3. Ren YF, Malmstrom HS. Effectiveness of antibiotic prophylaxis in third molar surgery: a meta-analysis of randomized controlled clinical trials. *J Oral Maxillofac Surg.* 2007;65:1909-21.
4. Arteagoitia I, Diez A, Barbier L, Santamaria G, Santamaria J. Efficacy of amoxicillin/clavulanic acid in preventing infectious and inflammatory complications following impacted mandibular third molar extraction. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2005;100:e11-8.
5. Halpern LR, Dodson TB. Does prophylactic administration of systemic antibiotics prevent postoperative inflammatory complications after third molar surgery?. *J Oral Maxillofac Surg.* 2007;65:177-85.
6. Poeschl PW, Eckel D, Poeschl E. Postoperative prophylactic antibiotic treatment in third molar surgery--a necessity?. *J Oral Maxillofac Surg.* 2004;62:3-8.
7. Monaco G, Tavernese L, Agostini R, Marchetti C. Evaluation of antibiotic prophylaxis in reducing postoperative infection after mandibular third molar extraction in young patients. *J Oral Maxillofac Surg.* 2009;67:1467-72.
8. Limeres J, Sanroman JF, Tomas I, Diz P. Patients' perception of recovery after third molar surgery following postoperative treatment with moxifloxacin versus amoxicillin and clavulanic acid: a randomized, double-blind, controlled study. *J Oral Maxillofac Surg.* 2009;67:286-91.
9. Kaczmarzyk T, Wichlinski J, Stypulkowska J, Zaleska M, Panas M, Woron J. Single-dose and multi-dose clindamycin therapy fails to demonstrate efficacy in preventing infectious and inflammatory complications in third molar surgery. *Int J Oral Maxillofac Surg.* 2007;36:417-22.
10. Kaczmarzyk T. Abuse of antibiotic prophylaxis in third molar

- surgeries. *J Oral Maxillofac Surg.* 2009;67:2551-2.
11. Cervino G, Cicchiù M, Biondi A, Bocchieri S, Herford AS, Laino L, *et al.* Antibiotic Prophylaxis on Third Molar Extraction: Systematic Review of Recent Data. *Antibiotics (Basel).* 2019;8:53.
  12. Blatt S, Al-Nawas B. A systematic review of latest evidence for antibiotic prophylaxis and therapy in oral and maxillofacial surgery. *Infection.* 2019;47:519-55.
  13. Lodi G, Azzi L, Varoni EM, Pentenero M, Del Fabbro M, Carrassi A, *et al.* Antibiotics to prevent complications following tooth extractions. *Cochrane Database Syst Rev.* 2021;2:Cd003811.
  14. Menon RK, Gopinath D, Li KY, Leung YY, Botelho MG. Does the use of amoxicillin/amoxicillin-clavulanic acid in third molar surgery reduce the risk of postoperative infection? A systematic review with meta-analysis. *Int J Oral Maxillofac Surg.* 2019;48:263-73.
  15. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *PLoS Med.* 2010;7:e1000251.
  16. Khojastepour L, Khaghaninejad MS, Hasanshahi R, Forghani M, Ahrari F. Does the Winter or Pell and Gregory Classification System Indicate the Apical Position of Impacted Mandibular Third Molars? *J Oral Maxillofac Surg.* 2019;77:2222.e1-9.
  17. Blum IR. Contemporary views on dry socket (alveolar osteitis): a clinical appraisal of standardization, aetiopathogenesis and management: a critical review. *Int J Oral Maxillofac Surg.* 2002;31:309-17.
  18. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. *Infect Control Hosp Epidemiol.* 1999;20:250-78.
  19. Lang MS, Gonzalez ML, Dodson TB. Do Antibiotics Decrease the Risk of Inflammatory Complications After Third Molar Removal in Community Practices?. *J Oral Maxillofac Surg.* 2017;75:249-55.
  20. Reiland MD, Ettlinger KS, Lohse CM, Viozzi CF. Does Administration of Oral Versus Intravenous Antibiotics for Third Molar Removal Have an Effect on the Incidence of Alveolar Osteitis or Postoperative Surgical Site Infections?. *J Oral Maxillofac Surg.* 2017;75:1801-8.
  21. Arteagoitia I, Ramos E, Santamaria G, Barbier L, Alvarez J, Santamaria J. Amoxicillin/clavulanic acid 2000/125 mg to prevent complications due to infection following completely bone-impacted lower third molar removal: a clinical trial. *Oral Surg Oral Med Oral Pathol Oral Radiol.* 2015;119:8-16.
  22. Lopez-Cedrun JL, Pijoan JI, Fernandez S, Santamaria J, Hernandez G. Efficacy of amoxicillin treatment in preventing postoperative complications in patients undergoing third molar surgery: a prospective, randomized, double-blind controlled study. *J Oral Maxillofac Surg.* 2011;69:e5-14.
  23. Marcussen KB, Laulund AS, Jorgensen HL, Pinholt EM. A Systematic Review on Effect of Single-Dose Preoperative Antibiotics at Surgical Osteotomy Extraction of Lower Third Molars. *J Oral Maxillofac Surg.* 2016;74:693-703.
  24. Ramos E, Santamaria J, Santamaria G, Barbier L, Arteagoitia I. Do systemic antibiotics prevent dry socket and infection after third molar extraction? A systematic review and meta-analysis. *Oral Surg Oral Med Oral Pathol Oral Radiol.* 2016;122:403-25.
  25. Xue P, Wang J, Wu B, Ma Y, Wu F, Hou R. Efficacy of antibiotic prophylaxis on postoperative inflammatory complications in Chinese patients having impacted mandibular third molars removed: a split-mouth, double-blind, self-controlled, clinical trial. *Br J Oral Maxillofac Surg.* 2015;53:416-20.
  26. Ataoglu H, Oz GY, Candirli C, Kiziloglu D. Routine antibiotic prophylaxis is not necessary during operations to remove third molars. *Br J Oral Maxillofac Surg.* 2008;46:133-5.
  27. Sekhar CH, Narayanan V, Baig MF. Role of antimicrobials in third molar surgery: prospective, double blind, randomized, placebo-controlled clinical study. *Br J Oral Maxillofac Surg.* 2001;39:134-7.
  28. Al Harbi MJ, Alomaym MAA, Mohammed Aldohan MF, Fahad Alkurdi I. Necessity of Antibiotics to Reduce Inflammatory Complications after Third Molar Extractions: A Prospective Study. *J Pharm Bioallied Sci.* 2019;11:S13-s7.
  29. Grossi GB, Maiorana C, Garramone RA, Borgonovo A, Creminelli L, Santoro F. Assessing postoperative discomfort after third molar surgery: a prospective study. *J Oral Maxillofac Surg.* 2007;65:901-17.
  30. Cisneros JM, Rodriguez-Bano J, Mensa J, Trilla A, Cainzos M. [Antimicrobial prophylaxis in surgery]. *Enferm Infecc Microbiol Clin.* 2002;20:335-40.
- Acknowledgements**  
We would like to express our gratitude and appreciation for Drs Roberto Pantoja, Ana Alarcón, Erita Cordero, Loreto Canto and Begoña Moreno whose support has been invaluable throughout this study. We also wish to thank all the Maxillofacial Surgery Team of San Borja Arriarán Clinical Hospital who have been a great source of support.
- Funding**  
The authors received no funding of any kind for this research.
- Conflict of interest**  
The authors have no conflicts of interest to declare.
- Ethics**  
This study was approved by the institutional ethical review board reference number 042016. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.
- Authors contributions**  
The authors NY, AC-L, CM and JV conceived and participated in the design of the study. BM participated in the enrollment of the patients, VV and NS as outcome assessors. NY, JV and LC participated as surgeons. Data collection was performed by IA-C. CM participated in the Statistical Analysis. JS-N and AC-L contributed to manuscript revisions. All the authors approved the final version of the manuscript and agree to be held accountable for the content therein.